Now there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician. Initial chapters focus on agents that are considered standard care: diuretics ACE inhibitors angiotensin receptor antagonists aldosterone antagonists beta-blockers The discussion moves to agents currently under investigation: Vasopressin antagonists erythropoietin Next, the authors consider some controversial drugs: inotropic agents antiarrhythmic drugs anticoagulants An insightful examination of pharmacogenetics considers: how studies of the genetic profile of patients helps determine which patient populations are most likely to respond to a given class of drugs the potential use of pharmacogenetics to tailor a pharmacologic regimen for maximum benefit and minimum risk Multidrug pharmacy for heart failure therapy An extremely helpful concluding chapter provides a roadmap of drugs with which to approach the patient with heart failure, along with an overview of the skills you need to use it most effectively. This straightforward, step-by-step algorithm will save you countless hours of research and help you make your prescribing decisions with confidence.

Now there is an up-to-date guide for optimizing pharmacologictherapy in treating patients with heart failure. Reflecting currentpractice at leading medical centers, Heart Failure:Pharmacologic Management provides both the biologic andpathologic underpinnings of each pharmacologic agent in currentuse. It also supplies detailed discussions of the clinicalinvestigations that support current understanding of the risks andbenefits associated with the use of these drugs. Thoroughreferences make the book useful to the novice as well as theexperienced clinician.Initial chapters focus on agents that are consideredstandard care:* * diuretics* ACE inhibitors* angiotensin receptor antagonists* aldosterone antagonists* beta-blockersThe discussion moves to agents currently underinvestigation:* * Vasopressin antagonists* erythropoietinNext, the authors consider some controversial drugs:* * inotropic agents* antiarrhythmic drugs* anticoagulantsAn insightful examination of pharmacogeneticsconsiders:* * how studies of the genetic profile of patients helps determinewhich patient populations are most likely to respond to a givenclass of drugs* the potential use of pharmacogenetics to tailor a pharmacologicregimen for maximum benefit and minimum riskMultidrug pharmacy for heart failure therapyAn extremely helpful concluding chapter provides a roadmap ofdrugs with which to approach the patient with heart failure, alongwith an overview of the skills you need to use it most effectively.This straightforward, step-by-step algorithm will save youcountless hours of research and help you make your prescribingdecisions with confidence.

Contributors.Introduction.1. Diuretics in congestive heart failure (Alicia Ross, Ray E.Hershberger and David H. Ellison).2. Use of digoxin in the treatment of heart failure (DeborahDeEugenio and Paul J. Mather).3. Renin-angiotensin system and angiotensin converting enzymeinhibitors in chronic heart failure (Rimvida Obeleniene and MarrickKukin).4. Angiotensin receptor blockers in the treatment of hartfailure (Anita Deswal and Douglas L. Mann).5. Beta blockers (Peter F. Robinson and Michael R. Bristow).6. Aldosterone antagonism in the pharmacological management ofchronic heart failure (Biykem Bozkurt).7. Inotropic therapy in clinical practice (Sharon Rubin andTheresa Pondok).8. Antiarrhythmic therapy in heart failure (Igino Contrafattoand Leslie A. Saxon).9. Treating the hypercoagulable state of heart failure:modifying the risk of arterial and venous thromboembolism (Geno J.Meril and Hoard H. Weitz).10. Vasodilator and nitrates (Abdul Al-Hesayen and John D.Parker).11. Natriuretic peptides fro the treatment of heart failure(Jonathan D. Sackner-Bernstein, Hal Skopicki and Keith D.Aaronson).12. Immune modulatory therapies in heart failure: usingmyocarditis to gain mechanistic insights (Grace Chan, Koichi FuseMei Sun, Bill Ayach and Peter P. Liu).13. The role of vasopressin and vasopressin antagonists in heartfailure (Olaf Hedrich, Maervin A. Konstam and James EricUdelson).14. Role of erythropoietin in the correction of anemia inpatients with heart failure (Revecca P. Streeter and Donna M.Mancini).15. Endothelin antagonism cardiovascular disease (SrinivasMurali).16. Pharmacogenetics (Richard Sheppard and Dennis M.McNamara).17. Management of diastolic dysfunction (Arthur M. Feldman andBonita Fakner).18. Multidrug pharmacy for treatment of heart failure: analgorithm for the clinician (Mariell Jessup).Index.